Zimbabwe has turned down a major American health deal worth $367m (272 million pounds) over five years due to Washington's request for sensitive biological samples.
This rejection became public following a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
A government representative later stated that the US was seeking biological samples for scientific study and commercial purposes while was unwilling to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more negotiations to reach a agreement agreeable to all parties so the nation's critical HIV programme can be sustained.
Wider Context
Zimbabwe's decision follows a similar situation in Kenya, where a court suspended a related health funding agreement after concerns were filed about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government agreements to boost transparency and responsibility.
As per statements, Sixteen African countries have so far agreed to these new agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Put simply, our nation would supply the raw materials for scientific discovery with no certainty that the final treatments would be available to our people if a future health crisis arise."
National Interest and International Frameworks
He also noted that the American exit from the global health body and its push of one-on-one health agreements were undermining systems previously established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This system is intended to guarantee that when a nation provides its information, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," he added.
"We encourage ongoing dialogue with our US partners on how subsequent collaboration could be arranged in a way that respects the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but suggested that talks should continue since much of the nation's Aids initiatives relied on external financing.
"If specific concerns arise, such as those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it said.
The situation emphasises the complex challenges between accepting crucial foreign assistance and protecting a country's data in an increasingly data-driven world.